Chemotherapy after surgery for high-risk pancreatic NET tumors
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This Phase 2 trial studies whether giving chemotherapy after surgery can lower cancer recurrence risk in people with high-risk pancreatic neuroendocrine tumors (NETs). It may help you by testing an added treatment after the tumor has been removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your pancreatic NET must be well-differentiated and confirmed by pathology.
- Your tumor must have been surgically removed 14 to 120 days before signing up, with no spread seen on a scan in the last 90 days.
- Your surgery must have removed all visible tumor (R0 or R1).
- Your Ki-67 test must be available and fall between 3% and 55% (done 14 to 90 days before signing up).
- You must meet the study’s “high-risk” scoring rules (Zaidi score 3 or higher) based on symptoms, tumor size, Ki-67, and lymph nodes.
- You must be well enough to participate (age 18+, recovery from surgery, and general health scores 0 to 2), and meet required blood/organ lab levels and contrast-scan safety.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether surgically removing as much of the tumor as possible (debulking) is better than not doing surgery for people with advanced pancreatic neuroendocrine tumors. It aims to see if this approach can improve outcomes.
This trial tests if removing as much tumor as possible through surgery before a targeted radiation therapy (PRRT) can help people with well-differentiated neuroendocrine tumors that have spread to the liver. The goal is to see if this approach works better than radiation therapy alone.
This trial tests whether adding a targeted drug called panitumumab to standard chemotherapy can help people with a certain type of pancreatic cancer that has spread. It is for patients whose tumors do not have a KRAS mutation and who have already had one line of chemotherapy.
This trial tests whether giving chemotherapy drugs (capecitabine and temozolomide) after surgery can help prevent pancreatic neuroendocrine tumors from coming back. You're eligible if your tumor was completely removed and shows intermediate to high risk of recurrence.
This Phase 2 trial tests a chemotherapy plan given before surgery (called “neoadjuvant” treatment) for people with pancreatic adenocarcinoma that looks resectable or borderline resectable on scans. The goal is to see how well this adaptive chemotherapy approach works and whether it can improve outcomes before an operation.
This trial tests a combination of chemotherapy drugs (NALIRIFOX) given before and after surgery for people with pancreatic cancer that is at high risk of coming back but can still be surgically removed. The goal is to see if this treatment helps improve outcomes.
Hear when a new Metastatic Malignant Neoplasm in the Liver trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.